argenx reports fourth quarter business update and full year 2017 financial results
March 01, 2018 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Management to host conference call today...
argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
February 22, 2018 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
February 22, 2018 Breda, the...
argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million
December 18, 2017 16:01 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Regulated information December 18, 2017...
argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering
December 13, 2017 19:26 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Regulated information - Inside...
argenx announces size of proposed public offering in the United States updated to 3.5 million ADSs
December 13, 2017 06:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Regulated information - Inside...
argenx announces launch of proposed public offering in the United States
December 11, 2017 16:09 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Regulated information - Inside...
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting
December 11, 2017 01:05 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Workshop to be held on Monday,...
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
December 11, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Favorable tolerability profile...
argenx to Present at Upcoming Investor Conferences
November 13, 2017 01:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
November 13, 2017 Breda, the...
argenx announces results of extraordinary shareholders' meeting 2017
November 07, 2017 06:00 ET
|
argenx SE
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
November 7, 2017 Breda, the Netherlands...